Sanofi ((SNYNF)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sanofi is conducting a Phase 3 clinical study titled ‘A Phase 3, Modified-double Blind, Multi-center Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents (2 to 17 Years of Age) in China.’ The study aims to evaluate the immunogenicity and safety of the MenACYW conjugate vaccine compared to existing meningococcal vaccines in China, focusing on children and adolescents.
The study tests the MenACYW conjugate vaccine, a biological intervention administered via intramuscular injection, intended to prevent meningococcal infections in young populations.
This interventional study is randomized and follows a parallel model with quadruple masking, ensuring that participants, care providers, investigators, and outcomes assessors are blinded to the interventions. The primary purpose is prevention.
The study is set to begin on August 14, 2025, with a primary completion date estimated 180 days later. The last update was also on August 14, 2025, indicating the study is not yet recruiting but is on track.
This update could influence Sanofi’s stock performance positively, as successful vaccine trials can boost investor confidence. Competitors in the vaccine market may closely watch these developments, as they could impact market dynamics in China.
The study is ongoing, with further details available on the ClinicalTrials portal.